Literature DB >> 17176527

The economics of HIV/AIDS in low-income countries: the case for prevention.

David Canning1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17176527     DOI: 10.1257/jep.20.3.121

Source DB:  PubMed          Journal:  J Econ Perspect        ISSN: 0895-3309


× No keyword cloud information.
  15 in total

1.  The welfare costs of HIV/AIDS in eastern Europe: an empirical assessment using the economic value-of-life approach.

Authors:  Julia Fimpel; Michael Stolpe
Journal:  Eur J Health Econ       Date:  2009-08-05

2.  The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya.

Authors:  Harsha Thirumurthy; Joshua Graff Zivin; Markus Goldstein
Journal:  J Hum Resour       Date:  2008

3.  The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study.

Authors:  Bjarne Robberstad; Jan Abel Olsen
Journal:  Cost Eff Resour Alloc       Date:  2010-04-16

4.  How to allocate limited healthcare resources: Lessons from the introduction of antiretroviral therapy in rural Mozambique.

Authors:  Zan M Dodson; Victor Agadjanian; Julia Driessen
Journal:  Appl Geogr       Date:  2016-11-25

5.  Health and labor supply in the context of HIV/AIDS: the long-run economic impacts on antiretroviral therapy().

Authors:  Harsha Thirumurthy; Joshua Graff Zivin
Journal:  Econ Dev Cult Change       Date:  2012-10-01

6.  A Game Theoretic Analysis of Competition Between Vaccine and Drug Companies during Disease Contraction and Recovery.

Authors:  Kjell Hausken; Mthuli Ncube
Journal:  Med Decis Making       Date:  2021-11-05       Impact factor: 2.749

7.  Global public goods and the global health agenda: problems, priorities and potential.

Authors:  Richard D Smith; Landis MacKellar
Journal:  Global Health       Date:  2007-09-22       Impact factor: 4.185

Review 8.  HIV prevention cost-effectiveness: a systematic review.

Authors:  Omar Galárraga; M Arantxa Colchero; Richard G Wamai; Stefano M Bertozzi
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

9.  Decisions of persons, the pharmaceutical industry, and donors in disease contraction and recovery assuming virus mutation.

Authors:  Kjell Hausken; Mthuli Ncube
Journal:  Health Econ Rev       Date:  2021-07-23

10.  Setting priorities for the health care sector in Zimbabwe using cost-effectiveness analysis and estimates of the burden of disease.

Authors:  Kristian Schultz Hansen; Glyn Chapman
Journal:  Cost Eff Resour Alloc       Date:  2008-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.